Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilars Deals 2023
Biosimilars Deals 2024
Chris Vindurampulle
Diversity
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
Paul Johns
PipCast®
PTE
Trade Marks
Webinars

NZ’s Pharmac Proposes Provisional Partnership with AstraZeneca to Fund Treatment of Cancer & Respiratory Conditions

Sep 13, 2024

On 13 September 2024, Pharmac, the New Zealand Pharmaceutical Management Agency, announced a proposal to fund four new cancer and respiratory treatments through a provisional partnership with AstraZeneca, commencing 1 January 2025.  The proposal includes the following AstraZeneca treatments involving biologics:

  • Enhertu® (trastuzumab deruxtecan) for the treatment of HER2 positive metastatic breast cancer; and
  • Synagis® (palivizumab) for prevention of severe illness caused by respiratory syncytial virus (RSV) in infants and young children at high risk of RSV.

Pharmac is seeking feedback on the proposal by email before 4pm, Monday 7 October 2024.